Back to Search
Start Over
Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.
- Source :
- Future Oncology; Apr2022, Vol. 18 Issue 9, p1055-1066, 12p
- Publication Year :
- 2022
-
Abstract
- Aim: We aimed to develop a new signature based on immune-related genes to predict prognosis and response to immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC). Materials & methods: Single-sample gene set enrichment was used to develop an immune-based prognostic signature (IPRS) for TNBC patients. We conducted multivariate Cox analysis to evaluate the prognosis value of the IPRS. Result: An IPRS based on 66 prognostic genes was developed. Multivariate Cox analysis indicated that the IPRS was an independent factor for prognosis. PD-1, PD-L1, PD-L2 and CTLA4 gene expression was higher in the low-risk group, suggesting IPRS could predict the response to immune checkpoint inhibitors. Conclusion: The IPRS might be a reliable signature to predict TNBC patients' prognosis and response to immune checkpoint inhibitors, but needs prospective validation. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14796694
- Volume :
- 18
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Future Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 155624273
- Full Text :
- https://doi.org/10.2217/fon-2021-0600